Suppr超能文献

使用选择性激动剂和新型Y1拮抗剂BIBP 3226对人脑动脉中的神经肽Y(NPY)受体进行表征。

Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.

作者信息

Abounader R, Villemure J G, Hamel E

机构信息

Laboratory of Cerebrovascular Research, Montreal Neurological Institute, Québec, Canada.

出版信息

Br J Pharmacol. 1995 Oct;116(4):2245-50. doi: 10.1111/j.1476-5381.1995.tb15060.x.

Abstract
  1. We have characterized pharmacologically the receptor subtype(s) responsible for the neuropeptide Y (NPY)-induced vasoconstriction in human cerebral arteries. NPY, PYY and several of their derivatives with well defined affinities at the known Y1 and Y2 receptor subtypes were used. Moreover, we tested the ability of the new Y1 receptor antagonist, BIBP 3226, to antagonize the NPY-induced cerebral vasoconstriction. 2. NPY, PYY and their agonists with high affinities at the Y1 receptor subtype ([Leu31-Pro34]-NPY and [Leu31-Pro34]-PYY) elicited strong, long lasting and concentration-dependent contractions of human cerebral arteries. Compounds with Y2 affinity such as PYY3-36 or NPY13-36 either elicited a submaximal contraction at high concentrations or failed to induce any significant vasomotor response. Also, the application of NPY or the specific Y1 agonist, [Leu31-Pro34]-NPY, to human cerebral vessels pretreated with the Y1 agonist, NPY13-36, resulted in contractile responses identical to those obtained when these compounds were tested without prior application of NPY13-36. 3. The order of agonist potency at the human cerebrovascular receptor was: [Leu31-Pro34]-NPY = [Leu31-Pro34]-PYY > or = NPY > PYY > PYY3-36 > > > NPY13-36, which corresponded to that reported previously at the neuronal and vascular Y1 receptors. 4. Increasing concentrations (10(-9)-10(-6) M) of the Y1 receptor antagonist, BIBP 3226, to human cerebral vessels caused a parallel and rightward shift in the NPY dose-response curves without any significant change in the maximal contractile response. The calculated pA2 was 8.52 +/- 0.13, a value compatible with the reported affinity at the rodent and human Y1 receptor. 5. We conclude that Y1 receptors exclusively, mediate the NPY-induced contraction in human cerebral arteries and we show that BIBP 3226 is a potent and competitive antagonist of this YI-mediated vasoconstriction.
摘要
  1. 我们已从药理学角度对负责神经肽Y(NPY)诱导人脑动脉血管收缩的受体亚型进行了特征描述。使用了NPY、PYY及其在已知Y1和Y2受体亚型上具有明确亲和力的几种衍生物。此外,我们测试了新型Y1受体拮抗剂BIBP 3226拮抗NPY诱导的脑血管收缩的能力。2. NPY、PYY及其在Y1受体亚型上具有高亲和力的激动剂([Leu31 - Pro34]-NPY和[Leu31 - Pro34]-PYY)引起人脑动脉强烈、持久且浓度依赖性的收缩。具有Y2亲和力的化合物,如PYY3 - 36或NPY13 - 36,要么在高浓度时引起次最大收缩,要么未能诱导任何显著的血管舒缩反应。同样,将NPY或特异性Y1激动剂[Leu31 - Pro34]-NPY应用于预先用Y1激动剂NPY13 - 36处理过的人脑血管,所产生的收缩反应与在未预先应用NPY13 - 36的情况下测试这些化合物时获得的反应相同。3. 人脑血管受体上激动剂效力的顺序为:[Leu31 - Pro34]-NPY = [Leu31 - Pro34]-PYY ≥ NPY > PYY > PYY3 - 36 >>> NPY13 - 36,这与先前在神经元和血管Y1受体上报道的顺序一致。4. 向人脑血管中增加Y1受体拮抗剂BIBP 3226的浓度(10⁻⁹ - 10⁻⁶ M)会导致NPY剂量 - 反应曲线平行且向右移动,而最大收缩反应无任何显著变化。计算得出的pA2为8.52 ± 0.13,该值与报道的在啮齿动物和人Y1受体上的亲和力相符。5. 我们得出结论,Y1受体单独介导NPY诱导的人脑动脉收缩,并且我们表明BIBP 3226是这种Y1介导的血管收缩的强效竞争性拮抗剂。

相似文献

引用本文的文献

10
The Translational Significance of the Neurovascular Unit.神经血管单元的转化意义
J Biol Chem. 2017 Jan 20;292(3):762-770. doi: 10.1074/jbc.R116.760215. Epub 2016 Dec 5.

本文引用的文献

1
Some quantitative uses of drug antagonists.药物拮抗剂的一些定量应用。
Br J Pharmacol Chemother. 1959 Mar;14(1):48-58. doi: 10.1111/j.1476-5381.1959.tb00928.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验